TY - JOUR
T1 - Vascular Dysfunction in Polycystic Kidney Disease
T2 - A Mini-Review
AU - Dennis, Melissa R.
AU - Pires, Paulo W.
AU - Banek, Christopher T.
N1 - Publisher Copyright:
© 2023 S. Karger AG, Basel. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Polycystic kidney disease (PKD) is one of the most common hereditary kidney diseases, which is characterized by progressive cyst growth and secondary hypertension. In addition to cystogenesis and renal abnormalities, patients with PKD can develop vascular abnormalities and cardiovascular complications. Progressive cyst growth substantially alters renal structure and culminates into end-stage renal disease. There remains no cure beyond renal transplantation, and treatment options remain largely limited to chronic renal replacement therapy. In addition to end-stage renal disease, patients with PKD also present with hypertension and cardiovascular disease, yet the timing and interactions between the cardiovascular and renal effects of PKD progression are understudied. Here, we review the vascular dysfunction found in clinical and preclinical models of PKD, including the clinical manifestations and relationship to hypertension, stroke, and related cardiovascular diseases. Finally, our discussion also highlights the critical questions and emerging areas in vascular research in PKD.
AB - Polycystic kidney disease (PKD) is one of the most common hereditary kidney diseases, which is characterized by progressive cyst growth and secondary hypertension. In addition to cystogenesis and renal abnormalities, patients with PKD can develop vascular abnormalities and cardiovascular complications. Progressive cyst growth substantially alters renal structure and culminates into end-stage renal disease. There remains no cure beyond renal transplantation, and treatment options remain largely limited to chronic renal replacement therapy. In addition to end-stage renal disease, patients with PKD also present with hypertension and cardiovascular disease, yet the timing and interactions between the cardiovascular and renal effects of PKD progression are understudied. Here, we review the vascular dysfunction found in clinical and preclinical models of PKD, including the clinical manifestations and relationship to hypertension, stroke, and related cardiovascular diseases. Finally, our discussion also highlights the critical questions and emerging areas in vascular research in PKD.
KW - Autosomal dominant polycystic kidney disease
KW - Autosomal recessive polycystic kidney disease
KW - End stage renal disease
KW - Fibrocystin
KW - Hypertension
KW - Polycystic kidney disease
KW - Polycystin
KW - Vascular dysfunction
KW - Wire myography
UR - http://www.scopus.com/inward/record.url?scp=85172425531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172425531&partnerID=8YFLogxK
U2 - 10.1159/000531647
DO - 10.1159/000531647
M3 - Review article
C2 - 37536302
AN - SCOPUS:85172425531
SN - 1018-1172
VL - 60
SP - 125
EP - 136
JO - Journal of Vascular Research
JF - Journal of Vascular Research
IS - 3
ER -